HLS Therapeutics Inc.

DB:74D Stock Report

Market Cap: €75.4m

HLS Therapeutics Valuation

Is 74D undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 74D when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 74D (€2.3) is trading below our estimate of fair value (€14.8)

Significantly Below Fair Value: 74D is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 74D?

Key metric: As 74D is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 74D. This is calculated by dividing 74D's market cap by their current revenue.
What is 74D's PS Ratio?
PS Ratio1.4x
SalesUS$56.94m
Market CapUS$79.62m

Price to Sales Ratio vs Peers

How does 74D's PS Ratio compare to its peers?

The above table shows the PS ratio for 74D vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average12x
HIGH Cantourage Group
29.2x38.6%€57.6m
APPH Apontis Pharma
2x17.3%€82.6m
0RX Redx Pharma
13.3x-37.6%€65.0m
2FJ0 Pierrel
3.4xn/a€92.8m
74D HLS Therapeutics
1.4x8.6%€111.6m

Price-To-Sales vs Peers: 74D is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (12x).

Price to Sales Ratio vs Industry

How does 74D's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

24 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.2.9x3.4%
74D HLS Therapeutics
 1.4x8.6%US$79.62m
74D 1.4xIndustry Avg. 2.9xNo. of Companies33PS0612182430+
24 CompaniesEstimated GrowthMarket Cap
Industry Avg.2.9x21.5%
74D HLS Therapeutics
 1.4x49.2%US$79.62m
No more companies

Price-To-Sales vs Industry: 74D is good value based on its Price-To-Sales Ratio (1.4x) compared to the European Pharmaceuticals industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is 74D's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

74D PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.4x
Fair PS Ratio1.3x

Price-To-Sales vs Fair Ratio: 74D is expensive based on its Price-To-Sales Ratio (1.4x) compared to the estimated Fair Price-To-Sales Ratio (1.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 74D forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€2.30
€4.07
+76.9%
41.4%€6.56€2.41n/a5
Nov ’25€2.14
€4.05
+89.4%
45.8%€6.37€2.18n/a4
Oct ’25€2.42
€3.76
+55.2%
46.3%€6.33€2.16n/a5
Sep ’25€2.14
€3.76
+75.5%
46.3%€6.33€2.16n/a5
Aug ’25€2.12
€3.95
+86.4%
41.6%€6.44€2.50n/a5
Jul ’25€2.22
€3.97
+78.9%
41.4%€6.45€2.54n/a5
Jun ’25€2.44
€3.97
+62.8%
41.4%€6.45€2.54n/a5
May ’25€3.08
€4.67
+51.5%
39.0%€7.30€2.89n/a5
Apr ’25€2.46
€4.91
+99.4%
37.4%€7.13€2.82n/a4
Mar ’25€2.76
€5.17
+87.2%
31.0%€7.02€2.98n/a4
Feb ’25€2.78
€4.92
+77.0%
30.7%€6.99€3.44n/a3
Jan ’25€2.50
€5.58
+123.3%
31.7%€7.65€3.42n/a4
Dec ’24€2.30
€5.68
+147.0%
32.3%€7.82€3.40n/a4
Nov ’24€3.28
€8.49
+159.0%
15.5%€9.90€6.38€2.144
Oct ’24€3.42
€8.40
+145.5%
15.5%€9.75€6.29€2.424
Sep ’24€3.10
€8.72
+181.2%
17.6%€10.21€6.18€2.144
Aug ’24€4.20
€9.56
+127.6%
22.9%€12.32€6.20€2.124
Jul ’24€4.14
€10.96
+164.7%
27.5%€15.76€6.77€2.225
Jun ’24€2.88
€11.36
+294.6%
25.9%€15.91€6.83€2.445
May ’24€3.86
€12.21
+216.3%
15.9%€15.80€9.98€3.085
Apr ’24€4.14
€12.45
+200.7%
16.0%€16.19€10.23€2.465
Mar ’24€5.95
€16.30
+174.0%
6.7%€18.16€15.17€2.765
Feb ’24€6.30
€15.91
+152.5%
6.6%€17.71€14.80€2.785
Jan ’24€6.50
€16.48
+153.6%
5.9%€18.06€15.44€2.505
Dec ’23€6.90
€16.51
+139.2%
6.0%€18.13€15.45€2.305
Nov ’23€7.30
€19.35
+165.1%
12.0%€23.80€17.27€3.285

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Aspen Pharmacare Holdings

R73.7b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.60

7D

-3.9%

1Y

-0.6%

Collegium Pharmaceutical

US$990.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

1.4%

1Y

25.0%

Pharming Group

€492.8m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.72

7D

-1.0%

1Y

-31.3%